A third-generation CD5-CAR incorporating NK-92 cell lines, which do not express CD5 on their surface, showed selective and significant tumoricidal activity towards various T-cell lines, including Jurkat, CCRF-CEM, and MOLT-4, as well as against primary CD5+ cells from human T-ALL and PTCL samples (85). This evidence concerns the gene CD5 and acute lymphoblastic leukemia.